Paper Details

  1. Home
  2. Paper Details

Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with comorbid depression: a meta-analysis of depression and cognitive outcomes.

Author: BeattieB Lynn, HsiungGing Yuek R, JacovaClaudia, LeePhilip E, SepehryAmir A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This study discusses the common occurrence of depression in people with Alzheimer's disease (AD) and highlights the potential benefits of adding antidepressants to existing AD treatments. The study notes that depression is now considered a recognized symptom of AD and suggests that treating depression may also improve cognitive symptoms in these patients.
Paper Details　
Original Abstract of the Article :
Comorbid depression is a leading neuropsychiatric complication in the Alzheimer's disease (AD) syndrome. In 2011, diagnostic criteria for AD were revised to include neuropsychiatric symptoms. It has been proposed that adding an antidepressant to existing treatment for AD could provide relief for not...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s40266-012-0012-5

データ提供：米国国立医学図書館（NLM）

The Impact of Selective Serotonin Reuptake Inhibitors on Alzheimer's Disease

This research delves into the challenging world of Alzheimer's disease (AD), specifically focusing on the role of selective serotonin reuptake inhibitors (SSRIs) in managing comorbid depression. This study utilized a meta-analysis approach to investigate the effects of SSRIs on both depressive and cognitive symptoms in AD patients. The authors discovered that incorporating SSRIs into existing AD treatment plans could potentially benefit not only depressive symptoms but also cognitive function. This finding offers a glimmer of hope for patients navigating the complex landscape of AD.

SSRIs Show Potential Benefits for Cognitive Function in AD

The study's findings suggest a potential for SSRIs to positively influence cognitive function in AD patients. This discovery is crucial because it underscores the multifaceted nature of AD and emphasizes the importance of addressing both psychological and cognitive aspects of the disease.

A Multifaceted Approach to Combating AD

This study reminds us that the desert of AD is a vast and intricate one. Just as a camel needs to adapt to various terrains, so too do AD patients require a multi-pronged approach to their care. This research suggests that treating depression might have a positive impact on cognitive function, emphasizing the importance of addressing all facets of the disease to maximize outcomes.

Dr. Camel's Conclusion

This research highlights the importance of a holistic approach to managing AD. SSRIs might be a valuable tool in the fight against this debilitating disease, offering a chance to improve not only mood but also cognitive function. This discovery is akin to finding a refreshing oasis in the vast desert of AD research.
Date :
  1. Date Completed 2013-08-29
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

23079957

DOI: Digital Object Identifier

10.1007/s40266-012-0012-5

Related Literature

Article Analysis
・Effective treatment of alzheimer's disease
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.